Beone Medicines Ltd. - American Depositary Shares (ONC) closed at $361.27 on November 2, 2026, down 2.4% from the previous close, on volume of 272,754 shares (30-day average 369,199).
Data as of November 2, 2026.
BeOne Medicines’ Lung Cancer Combo Trial Nears Key Data Milestone
TipRanks (Fri, 30-Oct 12:30 PM ET)
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026
Business Wire (Sat, 24-Oct 4:15 AM ET)
Business Wire (Fri, 23-Oct 10:15 AM ET)
BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 5
Business Wire (Thu, 22-Oct 6:01 AM ET)
BeOne Medicines Highlights Rapidly Accelerating Solid Tumor Franchise at ESMO 2026
Business Wire (Mon, 19-Oct 6:00 AM ET)
BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference
Business Wire (Tue, 1-Sep 6:00 AM ET)
Business Wire (Mon, 31-Aug 3:00 PM ET)
Business Wire (Mon, 31-Aug 6:00 AM ET)
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA
Business Wire (Tue, 25-Aug 10:40 AM ET)
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Beone Medicines Ltd. - American Depositary Shares trades on the NASDAQ stock market under the symbol ONC.
As of November 2, 2026, ONC stock price declined to $361.27 with 272,754 million shares trading.
ONC has a beta of 0.80, meaning it tends to be less sensitive to market movements. ONC has a correlation of 0.07 to the broad based SPY ETF.
ONC has a market cap of $40.87 billion. This is considered a Large Cap stock.
Last quarter Beone Medicines Ltd. - American Depositary Shares reported $2 billion in Revenue and $3.84 earnings per share. This beat revenue expectation by $114 million and exceeded earnings estimates by $2.40.
The top ETF exchange traded funds that ONC belongs to (by Net Assets): IBB, FBT, CGGO, CGGE, CGIE.
ONC has outperformed the market in the last year with a return of +17.2%, while the SPY ETF gained +11.7%. In the last 3 month period, ONC beat the market returning +12.2%, while SPY returned +1.7%. However, in the most recent 2 weeks ONC has underperformed the stock market by returning -2.1%, while SPY returned -1.5%.
ONC support price is $362.04 and resistance is $378.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ONC shares will trade within this expected range on the day.
